Denosumab therapy
Response of an aggressive periosteal aneurysmal bone cyst (ABC) of the radius to denosumab therapy
... of denosumab in two cases of spinal ABCs ...of denosumab therapy showed tumor regression in both ...to denosumab treatment and a follow-up of four ...
6
<p>Efficacy of denosumab therapy for a 21-year-old woman with Prader-Willi syndrome, osteoporosis and history of fractures: a case report</p>
... underwent denosumab treatment for ...of denosumab therapy, BMD increased by ...of denosumab treatment for osteoporosis in patients with ...findings, denosumab could represent an ...
5
Pre-treatment of daily teriparatide enhances the increase of bone mineral density in cortical bones by denosumab therapy
... The results for BMD are presented in Table 2 and Figures 1–3. Mean percent change in FN-BMD at 18 months was significantly higher in TPTD-pretreated group (p = 0.004) than in DMAb-alone group (Table 2 and Figure 3). Mean ...
6
Critical appraisal of denosumab in the treatment and prevention of postmenopausal osteoporosis and bone loss in patients undergoing hormone ablation
... With denosumab treatment, markers of bone resorption decreased rapidly and significantly and BMD increased at all measured ...of denosumab therapy, there was an RR reduction of 62% in new vertebral ...
21
Giant-cell tumor of bone: treatment options and role of denosumab
... Currently, denosumab is being evaluated in over 30 differ- ent studies for a wide range of indications, most of which involve bone ...of denosumab therapy, which are currently ...
6
Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study
... report, denosumab therapy resulted in a signifi- cant, early, and sustained increase in bone mineral density (BMD) and enhanced bone strength in the improvement of both cortical and trabecular bones ...that ...
6
Future of bisphosphonates and denosumab for men with advanced prostate cancer
... received denosumab 60 mg subcutaneously or placebo every 6 months (n = 734 in each ...months. Denosumab therapy was associated with a significant increase in BMD at all sites ...fact, ...
8
Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis
... Sixty-six Japanese female OP patients with RA were recruited at the Shinshu University School of Medicine and Showa-Inan General Hospital between 2014 and 2017 and were summarized in Table 1. The subjects were classified ...
7
A review of denosumab for the treatment of osteoporosis
... of denosumab over that period, BMD for the lumbar spine (n = 88) and for the total hip (n = 87) increased by ...that denosumab therapy mediated a progressive and substantial increase in BMD over 8 ...
9
Giant Cell Tumor Developing in Paget’s Disease of Bone: A Case Report with Review of Literature
... as denosumab [6, 7], a human monoclonal antibody, has shown early promising results in managing the GCT at difficult ...sites. Denosumab inhibits the development of osteoclasts and their activity thereby ...
5
Efficacy of denosumab in two cases with multiple-system atrophy and osteoporosis
... oral supplementation with vitamin D and calcium (762.5 mg of precipitated calcium carbonate, 200 IU of cholecalciferol, and 59.2 mg of magnesium carbonate). No complications including hypocalcemia occurred during the ...
6
Importance of antiresorptive therapies for patients with bone metastases from solid tumors
... of denosumab therapy in clinical trials will translate to long- term use in clinical ...of denosumab have been reported; however, a Phase III study in patients with nonmetastatic castration-resistant ...
11
Clinical utility of denosumab for treatment of bone loss in men and women
... treatment. Denosumab is a humanized monoclonal antibody and antiresorptive agent that works by decreasing the activity of the receptor activator of nuclear factor kappa B ...women, denosumab increased bone ...
6
Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
... before, denosumab is an antiresorptive com- pound with anti-fracture efficacy at all skeletal sites and, although direct comparative studies with fracture endpoints are lacking, completed trials with established ...
12
Denosumab-induced hypocalcaemia in metastatic castrate-resistant prostate cancer
... During admission, large doses of continuous i.v. 10% calcium gluconate (2.2 mmol/1 g/10 ml), up to 44 mmol/ day were required to maintain his serum calcium at the lower limit of normal. Calcium carbonate was switched to ...
5
Pharmacodynamics of Pre Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non small cell lung cancer (NSCLC): study protocol for a multicentre, open label, phase 1B/2, translational trial (POPCORN)
... More recently, immunotherapy blocking immune check- points expressed by T-lymphocytes (immune checkpoint in- hibition, ICI) demonstrated superior outcomes compared with chemotherapy in various settings in advanced NSCLC ...
9
Review Article Effect of denosumab, a fully human monoclonal antibody to RANKL, on bone mineral density and fractures: a meta-analysis
... the denosumab compared with the placebo group. Denosumab is a valuable new option for the treatment of osteoporosis and may be used as a first-line treatment in ...
10
Update on denosumab in the management of postmenopausal osteoporosis: patient preference and adherence
... In conclusion, current evidence underlines the neces- sity to personalize osteoporosis treatment, taking patient preference into account, especially in regards to frequency and route of administration. Current evidence ...
7
Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
... compared denosumab with other treatments to prevent or treat ...bisphosphonate therapy ≥ 1 ...of denosumab for postmenopausal osteopor- ...pared denosumab and alendronate in postmenopausal ...
9
Denosumab Use in a Patient with Bisphosphonate-Resistant Humoral Hypercalcemia of Malignancy
... receiving therapy. Denosumab is a fully human monoclonal antibody that binds to the mediator of bone resorption, receptor activator of nuclear factor kappa-B ligand ...
10